Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysis
Allergy2020Vol. 76(4), pp. 1053–1076
Citations Over TimeTop 10% of 2020 papers
Doreen Siegels, Annice Heratizadeh, Susanne Abraham, Jonas Binnmyr, Knut Brockow, Alan D. Irvine, Susanne Halken, Charlotte G. Mørtz, Carsten Flohr, Peter Schmid‐Grendelmeier, Lauri‐Ann Van der Poel, Antonella Muraro, Stephan Weidinger, Thomas Werfel, Jochen Schmitt
Abstract
The most robust, replicated high-quality trial evidence is present for the efficacy and safety of dupilumab for up to 1 year in adults. Robust trial evidence was further revealed for AZA, baricitinib and CSA. Methodological restrictions led to limited evidence-based conclusions for all other systemic treatments. Head-to-head trials with novel systemic treatments are required to clarify the future role of conventional therapies.
Related Papers
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)